Date: 10th November, 2026

To

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
Scrip Code: 544293

The Secretary
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1. G Block
Bandra - Kurla Complex, Bandra (East)
Mumbai- 400 051
Scrip Symbol: SURAKSHA

Dear Sir / Ma'am,

Sub: Outcome of the Board Meeting held today i.e. Tuesday, 10th November, 2026

Ref: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') as amended from time to time

Pursuant to Regulation 30 read with Part A of Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') as amended from time to time, we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e. Tuesday, 10th November, 2026, *inter alia*, considered and approved/noted the following:

1. Approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2026 and the same is enclosed along with the Limited Review Report issued by the Statutory Auditors of the Company, pursuant to Regulation 33 of SEBI Listing Regulations marked as **"Annexure-A";**

The aforesaid financial results are also being made available on the Company's website at www.surakshanet.com.

Please note that the meeting commenced at 03:00 P.M. (IST) and concluded at 03:40 P.M. (IST)

You are requested to take the same on record.

Thanking you.

For Suraksha Diagnostic Limited

Shreya Arora
Digitally signed by Shreya Arora
Date: 2026.11.10 16:26:56 +05'30'

Shreya Arora
Company Secretary & Compliance Officer
Membership No.: 30892

Encl.: as above

MSKA & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants

Infinity Benchmark, Unit 1302
13th Floor, Plot No. G-1, Block - EP & GP
Sector - V, Salt Lake
Kolkata, West Bengal 700 091

Independent Auditor's Review Report on unaudited standalone financial results of Suraksha Diagnostic Limited for the quarter and year to date ended September 30, 2026 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of Suraksha Diagnostic Limited


1. We have reviewed the accompanying statement of unaudited standalone financial results of **Suraksha Diagnostic Limited** (hereinafter referred to as 'the Company') for the quarter ended September 30, 2026 and the year to date results for the period from April 01, 2026 to September 30, 2026 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').

2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M S K A & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.105047W/W101187





Dipak Jaiswal
Partner
Membership No.: 063682
UDIN: 26063682HXMJLS2279

Place: Kolkata
Date: November 10, 2026

Suraksha
Clinic & Diagnostics

Suraksha Diagnostic Limited
Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India
(CIN : L85110WB2005PLC102265)
Website : www.surakshanet.com

Statement of unaudited standalone financial results for the quarter and year-to-date ended 30 September 2026

(₹ in lakhs)

Particulars	Quarter ended			Six month ended		Year ended
	30 September 2026 (Unaudited)	30 June 2026 (Unaudited)	30 September 2025 (Unaudited)	30 September 2026 (Unaudited)	30 September 2025 (Unaudited)	31 March 2026 (Audited)
Income						
I Revenue from operations	9,453.19	8,408.62	7,626.33	17,861.81	14,654.23	30,067.91
II Other income	196.98	156.41	96.72	353.39	206.29	435.23
III Total Income	**9,650.17**	**8,565.03**	**7,723.05**	**18,215.20**	**14,860.52**	**30,503.14**
IV Expenses						
Cost of materials consumed	1,049.41	971.16	880.38	2,020.57	1,749.18	3,610.01
Employee benefits expenses	1,441.34	1,385.26	1,298.98	2,826.60	2,540.46	5,167.00
Finance costs	478.67	367.00	271.76	845.67	537.61	1,233.99
Depreciation and amortisation expense	1,188.48	1,060.09	965.34	2,248.57	1,880.71	3,960.15
Impairment loss	(2.23)	75.96	20.45	73.73	(68.59)	46.71
Other expenses	3,576.31	3,084.32	3,029.19	6,660.63	5,652.12	11,763.77
Total expenses (IV)	**7,731.98**	**6,943.79**	**6,466.10**	**14,675.77**	**12,291.49**	**25,781.63**
V Profit before tax and exceptional items (III-IV)	**1,918.19**	**1,621.24**	**1,256.95**	**3,539.43**	**2,569.03**	**4,721.51**
VI Exceptional items	-	-	-	-	-	-
VII Profit before tax (V-VI)	**1,918.19**	**1,621.24**	**1,256.95**	**3,539.43**	**2,569.03**	**4,721.51**
VIII Income tax expense						
(i) Current tax	461.39	407.92	308.49	869.31	594.16	1,072.82
(ii) Tax pertaining to earlier period/years	-	11.39	-	11.39	-	-
(iii) Deferred tax	(73.18)	(56.27)	12.09	(129.45)	53.63	242.47
Total tax expense (VIII)	**388.21**	**363.04**	**320.58**	**751.25**	**647.79**	**1,315.29**
IX Profit for the period/year (VII-VIII)	**1,529.98**	**1,258.20**	**936.37**	**2,788.18**	**1,921.24**	**3,406.22**
X Other comprehensive income						
(a) Items that will not be reclassified subsequently to profit or loss						
(i) Remeasurement gain/(loss) of net defined benefit plan	(30.33)	19.02	(0.56)	(11.31)	25.44	76.09
(ii) Income tax effect on above	7.63	(4.78)	0.14	2.85	(6.40)	(19.15)
Other comprehensive income/(losses) for the period/year, net of tax	**(22.70)**	**14.24**	**(0.42)**	**(8.46)**	**19.04**	**56.94**
XI Total comprehensive income for the period/year	**1,507.28**	**1,272.44**	**935.95**	**2,779.72**	**1,940.28**	**3,463.16**
XII Paid-up equity share capital (face value - Rs. 2 per share)	1,041.62	1,041.62	1,041.62	1,041.62	1,041.62	1,041.62
XIII Other equity						23,938.04
XIV Earnings per equity share (Face Value of Rs 2 each)						
- Basic (Rs) (not annualised except for year end figures)	2.93	2.42	1.80	5.35	3.69	6.54
- Diluted (Rs) (not annualised except for year end figures)	2.93	2.42	1.80	5.35	3.69	6.54

MSKA & ASSOCIATES LLP * Chartered Accountants *

Suraksha Diagnostic Limited * Kolkata

Suraksha
Clinic & Diagnostics

Suraksha Diagnostic Limited
Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India
(CIN : U85110WB2005PLC102265)
Website : www.surakshanet.com
Unaudited Standalone Balance Sheet as at 30 September 2026

(₹ in lakhs)

Particulars	As at 30 September 2026 (Unaudited)	As at 31 March 2026 (Audited)
Assets		
Non-current assets		
a) Property, plant and equipment	21,490.52	16,853.33
b) Capital work-in-progress	1,655.69	3,498.61
c) Right-of-use assets	13,158.61	11,394.70
d) Intangible assets	110.43	110.48
e) Intangible assets under development	191.64	182.58
f) Financial assets		
i) Investments	680.81	631.11
ii) Loans	3,053.26	2,757.17
iii) Other financial assets	4,905.50	2,115.44
g) Non-current tax assets (net)	217.34	406.47
h) Other non-current assets	781.08	716.75
Total non-current assets (A)	**46,244.88**	**38,666.64**
Current assets		
a) Inventories	943.82	811.56
b) Financial assets		
i) Trade receivables	2,403.19	2,486.18
ii) Cash and cash equivalents	447.64	230.45
iii) Bank balances other than cash and cash equivalents	1,053.26	2,293.86
iv) Other financial assets	91.52	68.91
c) Other current assets	585.25	456.33
Total current assets (B)	**5,524.68**	**6,347.29**
Total Assets (A+B)	**51,769.56**	**45,013.93**
Equity and Liabilities		
Equity		
a) Equity share capital	1,041.62	1,041.62
b) Other equity	26,734.12	23,938.04
Total equity (A)	**27,775.74**	**24,979.66**
Liabilities		
Non-current liabilities		
a) Financial liabilities		
i) Borrowings	448.46	13.20
ii) Lease liabilities	13,188.53	11,209.10
iii) Other financial liabilities	1,384.21	2,187.30
b) Provisions	92.12	81.85
c) Deferred tax liabilities (net)	674.41	806.71
Total non-current liabilities (B)	**15,787.73**	**14,298.16**
Current liabilities		
a) Financial liabilities		
i) Borrowings	191.48	152.98
ii) Lease liabilities	1,459.47	1,425.29
iii) Trade payables		
- Total outstanding dues of micro enterprises and small enterprises	266.36	233.43
- Total outstanding dues other than above micro enterprises and small enterprises	1,945.51	1,708.91
iv) Other financial liabilities	3,909.55	1,915.97
b) Other current liabilities	414.76	284.71
c) Provisions	18.96	14.82
Total current liabilities (C)	**8,206.09**	**5,736.11**
Total liabilities (B+C)	**23,993.82**	**20,034.27**
Total equity and liabilities (A+B+C)	**51,769.56**	**45,013.93**

Suraksha Diagnostic Limited

Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India

(CIN : L85110WB2005PLC102265)

Website : www.surakshanet.com

Unaudited Standalone Statement of Cash Flow for the year-to-date ended 30 September 2026

(₹ in lakhs)

Particulars	30 September 2026 (Unaudited)	30 September 2025 (Unaudited)
Cash flow from operating activities		
Profit before tax	3,539.43	2,569.03
Adjustments for:		
Depreciation and amortisation expense	2,248.57	1,880.71
Finance costs	845.67	537.61
Interest on loans, deposits and IT refund	(243.52)	(187.82)
Unwinding of security deposit	(19.89)	(17.08)
Loss on sale of property, plant and equipment	6.15	29.25
Impairment Loss	73.73	(68.59)
Share based payment expenses	16.35	57.75
Liabilities/ provisions no longer required written back	(77.86)	-
Operating profit before working capital changes	**6,388.63**	**4,800.86**
Changes in operating assets and liabilities		
Adjustments for (increase) / decrease in operating assets		
Trade receivables	86.61	29.50
Inventories	(132.26)	(40.23)
Other financial assets	(95.46)	168.21
Other current assets	(87.29)	(217.70)
Adjustments for increase / (decrease) in operating liabilities		
Trade payables	347.39	137.72
Other current liabilities	130.05	28.37
Other financial liabilities	(0.51)	(300.50)
Provisions	(52.91)	17.86
Cash generated from operations	**6,584.25**	**4,624.09**
Income tax paid (net)	(679.31)	(855.30)
Net cash flows generated from operating activities (A)	**5,904.94**	**3,768.80**
Cash flows from investing activities		
Purchase of property, plant & equipment, other intangible assets and Intangible Asset under Development (including capital work-in-progress, capital advances and capital	(3,130.24)	(2,325.48)
Proceeds from sale of property, plant & equipment	16.39	9.17
Net Redemption in deposits with banks	(1,195.89)	330.11
Investment in Subsidiary/Other Company	(60.01)	(359.63)
Loan given to Subsidiaries	(244.91)	(130.69)
Interest received on bank deposits	(180.92)	154.95
Net cash flows used in investing activities (B)	**(4,795.58)**	**(2,321.57)**
Cash flow from financing activities		
Proceeds from borrowings	575.45	-
Repayment of borrowings	(101.69)	(321.33)
Payment of lease liabilities	(1,359.60)	(1,130.07)
Finance cost paid	(6.33)	(19.76)
Net cash flows used in financing activities (C)	**(892.17)**	**(1,471.16)**
Net increase in cash and cash equivalents (A+B+C)	217.19	(23.94)
Cash and cash equivalents at the beginning of the period	230.45	147.54
Cash and cash equivalents at the end of the period	**447.64**	**123.60**

MSKA & ASSOCIATES LLP * Chartered Accountants

Suraksha Diagnostic Limited * Kolkata

Suraksha
Clinic & Diagnostics

Notes to the unaudited standalone financial results

1. The unaudited standalone financial results for the quarter and year-to -date ended 30 September 2026 ("the financial results") of Suraksha Diagnostic Limited ("the Company") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) notified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulations")

2. These unaudited standalone financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on 10th November 2026. The statutory auditor have carried out limited review on these financial results and have issued an unmodified conclusion.

3. The Company is primarily engaged in the business of diagnostic centres for carrying out various pathology and radiology services and as such there are no separate reportable segments as per Ind AS 108 –'Operating Segments'.

4. These unaudited standalone financial results are also available on the Company's website (www.surakshanet.com) and on the stock exchange websites (www.bseindia.com and www.nseinda.com).

5. Previous period's/year's figures have been regrouped/reclassified wherever necessary to conform to current period's/ year's classification.

For and on behalf of Board of Directors of
Suraksha Diagnostic Limited

Dr. Somnath Chatterjee
Chairman & Joint Managing Director
DIN: 00137075

Place: Kolkata
Date: 10 November 2026

MSKA & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants

Infinity Benchmark, Unit 1302
13th Floor, Plot No. G-1, Block - EP & GP
Sector - V, Salt Lake
Kolkata, West Bengal 700 091

Independent Auditor's Review Report on unaudited consolidated financial results of Suraksha Diagnostic Limited for the quarter and year to date September 30, 2026 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Suraksha Diagnostic Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of **Suraksha Diagnostic Limited** (hereinafter referred to as 'the Holding Company'), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended September 30, 2026, and the year-to-date results for the period from April 01, 2026 to September 30, 2026 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Suraksha Speciality LLP	Subsidiary
2	Suraksha Radiology Private Limited	Subsidiary Company
3	Suraksha Advanced Radiology Private Limited	Subsidiary Company
4	Asian Institute of Immunology and Rheumatology LLP (AIIR)	Subsidiary
5	Fetomat Wellness Private Limited	Subsidiary Company
6	Suraksha Salvia LLP	Step-down subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results of six subsidiaries included in the Statement, whose interim financial results reflects total assets of Rs. 3,731.60 lakhs (before consolidation adjustments) as at September 30, 2026 and total revenues of Rs. 526.39 lakhs and Rs. 955.09 lakhs (before consolidation adjustments), total net loss after tax of Rs. 41.85 lakhs and Rs. 159.69 lakhs (before consolidation adjustments) and total comprehensive income of Rs. (41.85) lakhs and (159.69) lakhs (before consolidation adjustments) for the quarter ended 30 September 2026 and for the period from April 01, 2026 to September 30, 2026 respectively, and cash inflows (net) of Rs. 86.29 lakhs (before consolidation adjustments) for the period from 01 April 2026 to 30 September 2026, as considered in the statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and report of the other auditors.

For M S K A & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.105047W/W101187

Dipak Jaiswal
Partner
Membership No.: 063682
UDIN: 26063682XOCKHM7364

Place: Kolkata
Date: November 10, 2026

Suraksha
Clinic & Diagnostics

Suraksha Diagnostic Limited
Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India
(CIN : L85110WB2005PLC102265)
Website : www.surakshanet.com

Statement of unaudited consolidated financial result for the quarter and year-to-date ended 30 September 2026

(₹ in lakhs)

Particulars	Quarter ended			Six month ended		Year ended
	30 September 2026 (Unaudited)	30 June 2026 (Unaudited)	30 September 2025 (Unaudited)	30 September 2026 (Unaudited)	30 September 2025 (Unaudited)	31 March 2026 (Audited)
Income						
I Revenue from operations	9,907.11	8,764.54	7,872.90	18,671.65	15,131.53	31,041.41
II Other income	150.43	108.77	85.14	259.20	175.71	316.41
III Total Income	10,057.54	8,873.31	7,958.04	18,930.85	15,307.24	31,357.82
IV Expenses						
Cost of materials consumed	1,124.82	999.50	890.08	2,124.32	1,765.13	3,647.54
Employee benefits expenses	1,495.93	1,441.18	1,339.16	2,937.11	2,616.63	5,325.51
Finance costs	483.74	372.21	277.58	855.95	548.07	1,255.33
Depreciation and amortisation expense	1,260.75	1,128.22	1,014.32	2,388.97	1,962.56	4,144.83
Impairment loss	(9.23)	(5.20)	20.45	(14.43)	(68.59)	46.71
Other expenses	3,814.30	3,284.82	3,211.76	7,099.12	6,031.88	12,482.22
Total expenses (IV)	8,170.31	7,220.73	6,753.35	15,391.04	12,855.68	26,902.14
V Profit before tax and exceptional items (III-IV)	1,887.23	1,652.58	1,204.69	3,539.81	2,451.56	4,455.68
VI Exceptional items	-	-	-	-	-	-
VII Profit before tax (V-VI)	1,887.23	1,652.58	1,204.69	3,539.81	2,451.56	4,455.68
VIII Income tax expense						
(i) Current tax	465.39	412.92	309.83	878.31	597.65	1,077.69
(ii) Tax pertaining to earlier years	-	11.39	-	11.39	-	(0.05)
(iii) Deferred tax	(73.18)	(56.27)	12.09	(129.45)	53.63	237.79
Total tax expense (VIII)	392.21	368.04	321.92	760.25	651.28	1,315.43
IX Profit for the period/year (VII-VIII)	1,495.02	1,284.54	882.77	2,779.56	1,800.28	3,140.25
X Other comprehensive income						
(a) Items that will not be reclassified subsequently to profit or loss						
(i) Remeasurement gain/(loss) of net defined benefit plan	(30.33)	19.02	(0.56)	(11.31)	25.44	76.09
(ii) Income tax effect on above	7.63	(4.78)	0.14	2.85	(6.40)	(19.15)
Other comprehensive income/(losses) for the period/year, net of tax	(22.70)	14.24	(0.42)	(8.46)	19.04	56.94
XI Total comprehensive income for the period/year	1,472.32	1,298.78	882.35	2,771.10	1,819.32	3,197.19
XII Profit for the period/year attributed to						
Owners of the parent	1,500.94	1,300.80	898.64	2,801.74	1,838.38	3,218.71
Non- controlling interests	(5.92)	(16.26)	(15.87)	(22.18)	(38.10)	(78.46)
	1,495.02	1,284.54	882.77	2,779.56	1,800.28	3,140.25
XIII Other comprehensive income for the period/year attributable to						
Owners of the parent	(22.70)	14.24	(0.42)	(8.46)	19.04	56.94
Non- controlling interests	-	-	-	-	-	-
	(22.70)	14.24	(0.42)	(8.46)	19.04	56.94
XIV Total comprehensive income for the period/year attributable to						
Owners of the parent	1,478.24	1,315.04	898.22	2,793.28	1,857.42	3,275.65
Non- controlling interests	(5.92)	(16.26)	(15.87)	(22.18)	(38.10)	(78.46)
	1,472.32	1,298.78	882.35	2,771.10	1,819.32	3,197.19
XV Paid-up equity share capital (face value - Rs. 2 per share)	1041.62	1041.62	1041.62	1041.62	1041.62	1041.62
XVI Other equity						23,443.28
XVII Earnings per equity share (Face Value of 2 each (Rs))						
- Basic (Rs) (not annualised except for year end figures)	2.88	2.50	1.73	5.38	3.53	6.18
- Diluted (Rs) (not annualised except for year end figures)	2.88	2.50	1.73	5.38	3.53	6.18

MSKA & ASSOCIATES LLP * Chartered Accountants *

Suraksha Diagnostic Limited * Kolkata *

Suraksha Diagnostic Limited
Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India
(CIN : U85110WB2005PLC102265)
Website : www.surakshanet.com
Unaudited Consolidated Balance Sheet as at September 30, 2026

(₹ in lakhs)

Particulars	As at September 30, 2026 (Unaudited)	As at March 31, 2026 (Audited)
Assets		
Non-current assets		
a) Property, plant and equipment	24,095.75	19,357.85
b) Capital work-in-progress	1,669.97	3,511.63
c) Right-of-use assets	13,352.49	11,605.51
d) Goodwill	388.01	388.01
e) Intangible assets	111.59	112.16
f) Intangible Assets under Development	191.64	182.58
g) Financial assets		
i) Other financial assets	4,923.42	2,161.86
h) Non-current tax assets (net)	686.44	419.72
i) Other non-current assets	809.56	814.66
Total non-current assets (A)	**46,228.87**	**38,553.98**
Current assets		
a) Inventories	992.66	814.31
b) Financial assets		
i) Trade receivables	2,526.53	2,275.77
ii) Cash and cash equivalents	566.88	321.41
iii) Bank balances other than cash and cash equivalents	1,148.69	2,313.43
iv) Other financial assets	100.02	68.91
c) Other current assets	506.06	463.83
Total current assets (B)	**5,840.84**	**6,257.66**
Total Assets (A+B)	**52,069.70**	**44,811.64**
Equity and Liabilities		
Equity		
a) Equity share capital	1,041.62	1,041.62
b) Other equity	26,581.57	23,443.28
c) Equity attributable to owners of the parent (a+b+c)	**27,623.19**	**24,484.90**
d) Non Controlling interest	(119.11)	(137.18)
Total equity (A)	**27,504.08**	**24,347.72**
Liabilities		
Non-current liabilities		
a) Financial liabilities		
i) Borrowings	450.04	17.76
ii) Lease liabilities	13,367.74	11,411.32
iii) Other Financial liability	1,387.57	2,187.30
b) Provisions	93.12	82.55
c) Deferred tax liabilities (net)	806.71	800.05
Total non-current liabilities (B)	**16,105.18**	**14,498.98**
Current liabilities		
a) Financial liabilities		
i) Borrowings	195.83	155.68
ii) Lease liabilities	1,494.78	1,449.35
iii) Trade payables		
- Total outstanding dues of micro enterprises and small enterprises	266.36	233.43
- Total outstanding dues other than above micro enterprises and small enterprises	2,062.65	1,852.75
iv) Other financial liabilities	3,972.93	1,928.37
b) Other current liabilities	447.47	330.54
c) Provisions	20.42	14.82
Total current liabilities (C)	**8,460.44**	**5,964.94**
Total liabilities (B+C)	**24,565.61**	**20,463.92**
Total equity and liabilities (A+B+C)	**52,069.70**	**44,811.64**

MSKA & ASSOCIATES LLP * Chartered Accountants *

Suraksha Diagnostic Limited Kolkata

Suraksha
Clinic & Diagnostics

Suraksha Diagnostic Limited
Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India
(CIN : L85110WB2005PLC102265)
Website : www.surakshanet.com

Unaudited Consolidated Statement of Cash Flows for the year-to-date ended 30 September 2026

(₹ in lakhs)

Particulars	30 September 2026 (Unaudited)	30 September 2025 (Unaudited)
Cash flow from operating activities		
Profit before tax	3,539.81	2,451.56
Adjustments for:		-
Depreciation and amortisation expenses	2,388.97	1,962.57
Finance costs	855.95	548.07
Interest on loans, deposits and IT refund	(136.48)	(146.12)
Unwinding of security deposit	(20.05)	(17.20)
Loss on sale of property, plant and equipment	6.15	29.25
Impairment Loss	(14.43)	(68.59)
Share based payment expenses	16.36	57.75
Liabilities/ provisions no longer required written back	(77.86)	(0.31)
Operating profit before working capital changes	**6,558.42**	**4,816.98**
Changes in operating assets and liabilities		
Adjustments for (increase) / decrease in operating assets		
Trade receivables	(236.33)	100.19
Inventories	(178.35)	(38.57)
Other financial assets	(110.10)	168.64
Other current assets	77.78	(408.85)
Adjustments for increase / (decrease) in operating liabilities		-
Trade payables	320.69	257.70
Other current liabilities	116.92	(70.31)
Other financial liabilities	57.67	(302.63)
Provisions	(51.15)	17.86
Cash generated from operations	**6,555.54**	**4,541.01**
Income tax paid (net)	(676.11)	(871.70)
Net cash flows generated from operating activities (A)	**5,879.44**	**3,669.31**
Cash flows from investing activities		
Purchase of property, plant & equipment, other intangible assets and intangible asset under development (including capital work-in-progress, capital advances and capital creditors)	(3,359.05)	(2,346.15)
Proceeds from sale of property, plant & equipment	16.39	9.17
Net Redemption/(Investments) in deposits with banks	(1,596.48)	320.23
Investment in Company	-	(327.10)
Interest received on bank deposits	182.12	163.32
Net cash flows used in investing activities (B)	**(4,757.02)**	**(2,180.53)**
Cash flow from financing activities		
Contribution from non-controlling interests	40.00	-
Proceeds from borrowings	575.45	-
Repayment of borrowings	(103.03)	(332.76)
Payment of lease liabilities	(1,381.46)	(1,149.35)
Finance cost paid	(7.91)	(20.63)
Net cash flows used in financing activities (C)	**(876.95)**	**(1,502.74)**
Net increase in cash and cash equivalents (A+B+C)	**245.47**	**(13.96)**
Cash and cash equivalents at the beginning of the year	321.41	224.68
Cash and cash equivalents at the end of the year	**566.88**	**210.72**

Suraksha
Clinic & Diagnostics

Notes to the unaudited consolidated financial results

1. The Unaudited consolidated financial results for the quarter and year-to-date ended 30 September 2026 ("the financial results") of Suraksha Diagnostic Limited ("the Holding Company") and its subsidiary (Holding company and subsidiaries together referred to as 'the group') have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) notified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the regulations").

2. These unaudited consolidated financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on 10th November 2026. The statutory auditor have carried out limited review on these financial results and have issued an unmodified conclusion.

3. The Group is primarily engaged in the business of diagnostic centres for carrying out various pathology and radiology services and as such there are no separate reportable segments as per Ind AS 108 –'Operating Segments'.

4. These Unaudited consolidated financial results are also available on the Holding Company's website (www.surakshanet.com) and on the stock exchange websites (www.bseindia.com and www.nseinda.com).

5. Previous period's/year's figures have been regrouped/reclassified wherever necessary to conform to current period's/ year's classification.

For and on behalf of Board of Directors of
Suraksha Diagnostic Limited

Dr. Somnath Chatterjee
Chairman & Joint Managing Director
DIN: 00137075

Place: Kolkata
Date: 10 November 2026